DE10020812A1 - Use of naphthindazole-4,9-quinones as antiparasitic agents - Google Patents

Abstract

The invention relates to pharmaceutical compositions which are characterised in that they contain at least one of the compounds of general formula (I), to their pharmacologically suitable salts and to the use of compounds of general formula (I) or their pharmacologically suitable salts for prophylactic administration or for therapeutic treatment of a parasitic infection caused by <i>Trypanosoma </i>spp., <i>Leishmania </i>spp., <i>Plasmodium </i>spp., <i>Cryptosporidium parvum</i>, <i>Eimeria </i>spp., <i>Toxoplasma gondii </i>or <i>Pneumocystis </i>spp.

Description

The invention relates to pharmaceutical compositions characterized by the content of at least one of the compounds of general formula (I)

and their pharmacologically acceptable salts and the use of Compounds of general formula (I) or their pharmacologically acceptable Salts for the prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp.

Thus, the invention relates to a group of chemically defined substances Scaffold, which specific antiparasitic effects in vitro and in vivo (Animal, human) have. The skeletons are among the naphthoquinone and related anthraquinone and phenanthrenequinone types.

The human pharmacological use of naphthoquinones studied so far is strongly limited by the high toxicity, which is an in vivo application in humans almost impossible.

Previously used naphthoquinones were experimentally investigated as cytostatics. Only the naphthoquinone "Atovaquone" (Wellvone®) was used in monotherapy  for the treatment of Pneumocystis carinii (PcP) infections and in the Combination therapy with proguanil for the treatment of plasmodium infections used. Atovaquone shows in monotherapy of Pneumocystis carinii (PcP) Infections in HIV coinfections have good effects, however, with longer therapies due to the rapid development of resistance of the pathogens only partially applicable. Monotherapy in malaria is due to the rapid development of resistance of the Pathogen not possible. Another disadvantage is the very bad Bioavailability and the high daily dose of 3 times 750 mg per day.

Other antiprotozoal compounds are pentamidine isethionate, melarsoprol and Glucantime. Taken together, they show high toxicity with only a slight toxicity therapeutic benefit. According to current understanding and legal requirements would be It is no longer possible to authorize these drugs, which are more than 70 years old.

Thus, there is an urgent need for new drugs and medicines for treatment or to provide prophylaxis of parasitic infections. Especially lacks pharmaceutical compositions for prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp.

The present invention is therefore based on the object compounds for prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. to provide as well as to provide pharmaceutical compositions, which at least one of the prophylactic or therapeutic Treatment of parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. used compounds.  

According to the invention, this object is achieved by the use of the compounds of the general formula (I)

where R ^{1 is} hydrogen or a group
- (CH ₂ ) _m -CH = CH- (CH ₂ ) _8-m -H,
- (CH ₂ ) _m -C-C- (CH ₂ ) _8-m -H,
- (CH ₂ ) _n -R ⁷ ,

-C ₂ H ₄ -C~CR ¹² ,
-CH ₂ -C~C-CH ₂ -R ¹² ,
-C~CC ₂ H ₄ -R ¹²
means and
R ² , R ³ , R ⁴ , R ⁵ and R ^{6 are} independently hydrogen or the groups
R ⁷ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN, -OH,
- (CH ₂ ) _o -R ¹⁴ ,
-O- (CH ₂ ) _o -R ¹² ,
-S- (CH ₂ ) _o -R ¹² ,

R ³ together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ³ together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring forms a further fused five- or six-membered heterocycle, wherein R ³ and / or R ^{4 represent} a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁴ together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{4 forms} together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring another condensed five- or six-membered heterocycle, wherein R ⁴ and R ⁵ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁵ together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring forms a further fused benzene or naphthalene ring, which optionally carries further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{5 forms} together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring another fused five- or six-membered heterocycle, wherein R ⁵ and R ⁶ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ^{7 is} -R ¹² , -OR ⁸ or -SR ⁸ ,
R ⁸ and R ^{8 '} independently of one another denote an alkyl group having 1 to 4 carbon atoms,
R ^{9 is} an alkyl group having 1 to 4 carbon atoms or a group of the structure
-NH-R ⁸ ,

represents,
R ^{10 is} -R ¹² , -R ⁸ or -OR ⁸ ,
R ^{11 is} -R ⁸ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -OH, -OR ⁸ ,
R ¹² , -R ^{12 '} , -R ^{12 "} , -R ^12"' , -R ^{12 ""} independently of one another are -H, -F, -Cl, -Br or -I,
R ^{13 is} -R ⁸ , -R ¹² or a group of the following structure:
-C ₂ H ₄ -C~CR ¹² , -CH ₂ -C~C-CH ₂ -R ¹² , -C~CC ₂ H ₄ -R ¹² ,
R ^{14 is} -CH ₃ , -R ⁷ , -SH,
R ¹⁵ , -R ^{15 '} , -R ^{15 "} , -R ^15"' , -R ^{15 ""} independently of one another
-R ⁷ , -R ⁸ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN or
-O- (CH ₂ ) _o -R ¹² , -S- (CH ₂ ) _o -R ¹² , - (CH ₂ ) _o -R ¹²
stand,
R ¹⁶ and R ^{16 '} independently of one another denote -H or -R ⁸ ,
R ^{17 is} -R ⁷ , -CF ₃ , -NO ₂ , -CN, -SH, -OH or -NH ₂ ,
m for 0 to 8,
n for 1 to 10,
o for 1 to 5 and
p is 0 to 4,
and their pharmacologically acceptable salts and dimers or trimers of the compounds of the general formula (I) or the pharmaceutical compositions containing at least one compound of the general formula (I) or their pharmacologically acceptable salts or dimers or trimers of the compounds of the general formula (I) for the prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. solved.

Preferred for use for prophylactic administration or therapeutic treatment of parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. are the compounds of general formula (I) wherein
R ^{1 is} hydrogen or a group
- (CH ₂ ) _m -CH = CH- (CH ₂ ) _2-m -H,
- (CH ₂ ) _m -C-C- (CH ₂ ) _2-m -H,
- (CH ₂ ) _n -R ⁷ ,

stands,
R ^{7 is} -R ¹² , -OR ⁸ or -SR ⁸ ,
R ⁸ and R ^{8 '} independently of one another denote an alkyl group having 1 to 4 carbon atoms,
R ¹² , -R ^{12 '} , -R ^{12 "} , -R ^12"' , -R ^{12 ""} independently of one another are -H, -F, -Cl, -Br or -I,
R ¹⁵ , -R ^{15 '} , -R ^{15 "} , -R ^15"' , -R ^{15 ""} independently of one another
R ⁷ , R ⁸ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} or -CN are and
m for 0 to 2 and
n stands for 1 to 4.

Especially preferred for use for the prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. are the compounds of general formula (I) wherein
R ^{1 is} hydrogen, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, tert-amyl, n-hexyl, pent-3-yl, 1,2 -Dimethylpropyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, 1,2,2-trimethylpropyl, 2-methylhept-5-yl, allyl, methallyl, crotyl, 2-ethyl-2-hexenyl, 5-hexenyl , 2-methyl-2-butenyl, 2-methyl-3-butenyl, 1-buten-3-yl, 2-methyl-1-buten-4-yl, 2-methyl-2-buten-4-yl, 3 Methyl-1-buten-3-yl, propargyl, 1-butyn-3-yl, 2-butynyl, 2-chloroethyl, 2-chloropropyl, 3-chloropropyl, 2-chlorobut-2-yl, 2-chloro-2 -methylpropyl, 2-fluorobut-2-yl, 2-fluoro-2-methylpropyl, 1-fluoroprop-2-yl, 1-chloro-2-methylprop-2-yl, 2,2,2-trifluoroethyl, hydroxymethyl, 2 -Hydroxyethyl, 3-hydroxypropyl, 1-hydroxyprop-2-yl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-2-methylpropyl, 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl, 1-methoxyprop -2-yl, 3-methoxybutyl, 1-methoxybut-2-yl, 1-methoxy-2-methylprop-2-yl, 1-ethoxy-2-methylprop-2-yl, 2-methoxybutyl, 4-methoxybutyl, Cyc lopropyl, cyclopentyl, cyclohexyl, 2-methylmercaptoethyl, 2-ethylmercaptoethyl, 3-methylmercaptopropyl, 3-methylmercaptobutyl, 1-methylmercaptobut-2-yl, 1-methylmercapto-2-methylprop-2-yl, 2-methylmercaptobutyl, phenyl, 4- Chlorophenyl, 3,4-dichlorophenyl, o-tert-butylphenyl, m-tert-butylphenyl, p-tert-butylphenyl, o-methoxyphenyl, m-methoxyphenyl, p-methoxyphenyl, o-methylphenyl, m-methylphenyl, p Methylphenyl, 4-methoxy-3-chlorophenyl, 2-methyl-4-chlorophenyl, benzyl, 2,6-dichlorobenzyl, 2-chloro-6-fluorobenzyl, 2,6-difluorobenzyl, o-chlorobenzyl, m-chlorobenzyl or p -Chlorbenzyl stands.

The naphthindazole-4,9-quinones were synthesized by H. Laatsch and structurally elucidated (Laatsch, H. Liebigs Ann. Chem., 1985, 251-274). The synthesis of Naphthindazole-4,9-quinones are prepared according to the method described in German Patent DE 38 31 332 described synthesis scheme. All connections were with help spectroscopic methods (H / C-NMR, mass spectroscopy, UV, IR Spectroscopy) structurally characterized. In the above publication like also in subsequent communications, the author (s) did not report that the described naphthindazole-4,9-quinones show antiparasitic effects.  

It is known that naphthoquinones are a structural class with biological activity form. A disadvantage of the investigated naphthoquinones was their high toxicity towards cells and mammals. The high toxicity was in animal experiments Rats and mice (Sepúvelda-Boza, S., Cassels, B.K. Plant metabolites active against Trypanosoma cruzi. Planta Med. 1996, 62, 98-105). For the compounds of the general formula (I), the naphthindazole-4,9-quinones, neither antiparasitic nor toxicological effects were described. Only herbicidal actions against phytopathogenic fungi were by H. Laatsch described (Offenlegungsschrift DE-A 21 07 053).

It has unexpectedly been found that the compounds of general formula (I)

and their pharmacologically acceptable salts or dimers or trimers, wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ^{6 have} the abovementioned meaning, have high antiparasitic activity with very low toxicity.

The high antiparasitic effect as well as the very low toxicity could be observed in the animal on Example of the mouse can be detected.

The following table lists the compounds of the general formula (I) which have been used in the pharmacological investigations.

The naphthindazole-4,9-quinones of the general formula (I) are characterized by a Excellent effectiveness against a wide range of veterinary and human pathogenic parasites, especially against Leishmania and Crypto sporidia. They show high compatibility in the in vivo mouse model and can be found in Antiparasitic agents are used for therapeutic use.

According to the invention, the antiparasitic compounds of the general formula (I) for the prophylaxis of infection and / or for the treatment of an existing infection used therapeutically.

The following table lists the microbial pathogens against which the compounds of the general formula (I) and illustrates which diseases caused by these microbial pathogens.  

illness Microbial pathogen a) African Humane Trypanosomiasis Trypanosoma spp. b) South American trypanosomiasis Trypanosoma spp. c) Visceral Leishmaniasis Leishmania spp. d) cutaneous and mucocutaneous leishmaniasis Leishmania spp. e) Canine leishmaniasis Leishmania spp. f) malaria Plasmodium spp. g) babesiosis Babesia spp. h) Neosporidosis Neospora caninum i) Sarcocystosis Sarcocystis spp. j) cryptosporidiosis Cryptosporidium spp. k) Coccidiosis Eimeria spp., Isospora spp. l) Human Toxoplasmosis Toxoplasma gondii m) Feline toxoplasmosis Toxoplasma spp. n) pneumocystosis Pneumocystis carinii

The subject of the present invention is also the provision of pharmaceutical compositions containing at least one of the compounds of general formula (I),

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ^{6 have} the meanings given above.

The compounds of general formula (I) may be administered by themselves or in the form of a pharmacologically acceptable salt. Suitable examples of these salts of the compounds of general formula (I) include acid addition salts with organic or inorganic acids. As acids which form an acid addition salt of the compounds of the general formula (I), there may be mentioned the following:
Sulfuric acid, sulfonic acid, phosphoric acid, nitric acid, perchloric acid, hydrobromic acid, hydrochloric acid, formic acid, acetic acid, propionic acid, butyric acid, succinic acid, oxalic acid, glucolic acid, lactic acid, malic acid, tartaric acid, fumaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, salicylic acid, p-aminosalicylic acid, ambonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylene sulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, quinic acid, o-methylmandelic acid, hydrogenbenzenesulfonic acid, methionine, tryptophan, lysine, arginine, picric acid , Adipic acid or do-tolyltartaric acid.

The compounds of general formula (I) and their pharmacological Compatible salts can be administered alone or in a known manner by Stretching at least one of the compounds of general formula (I) with Solvents, carriers and / or animal feed, optionally using of emulsifiers and / or dispersants, in the usual formulations be transferred. The pharmaceutical compositions may take the form of Solutions, suspensions, dispersions, emulsions, creams, ointments, pastes, Powder, granules, tablets, suppositories, capsules or dragees can be used.

The application depends on the parasite to be treated and should the Killing or at least a multiplication or growth restriction of the Cause parasites.

For example, corresponding formulations are obtained by mixing at least one compound of general formula (I) with solvents, Carriers and / or animal feed, optionally using Emulsifiers and / or dispersants, wherein in the case of water as  Diluent also other organic solvents are used can.

The solvents used for the formulations according to the invention are aromatics, chlorinated aromatics, paraffins, alcohols, water, ketones, amines, ethanolamine, Dimethylformamide and / or dimethyl sulfoxide. As carriers are natural Ground minerals, such as kaolin, clays, talc, chalk or synthetic minerals such as finely divided silica or silicates used. As emulsifiers find non-ionic and ionic emulsifiers, such as Polyoxyethylene fatty alcohol ethers, alkyl sulfonates or arylsulfonates use. When Dispersants include lignin, liquors, methylcellulose and as Capsule bases for tablets ethylcellulose, starch, lactose, alkaline earth fatty acids or magnesium stearate in question.

The antiparasitic pharmaceutical compositions of the invention contain at least one of the compounds of general formula (I) in one Amount between 0.1 and 99 wt .-%.

The antiparasitic pharmaceuticals according to the invention preferably contain Compositions of at least one of the compounds of general formula (I) in an amount between 50 and 99 wt .-%.

Of the pharmaceutical compositions of the invention are the Patients depending on the clinical picture and its physical stature a daily dose between 0.5 and 1500 mg based on the compounds of the general formula (I) administered.

The compounds of the general formula (I) are applied by systemically or locally administered to the organism. After Forth, W., Henschler, D., Rummel, W., Strong, R. (1996) General and Special Pharmacology and Toxikologie, Spektrum Verlag, describes the oral, cutaneous, nasal, parenteral, buccal or anal administration and under cutaneous administration Apply to the skin and / or mucous membranes without systemic effects achieve understood.  

Of particular interest are pharmaceutical according to the invention Compositions in which the processing of the compounds of the general formula (I) for systemic and local administration to particulate Drug forms takes place.

In addition to the usual formulations, the processing is separate To name nanosuspensions that the systemic and local application of Active ingredients optimized.

For nanosuspensions, solid-liquid nanoparticles (SLN) or liposomes with one average particle diameter of 0.1 to 3 microns are pharmaceutical Compositions referred to as particulate drug forms.

The pharmaceutical compositions according to the invention are used for therapeutic treatment or prophylactic use in case of parasitic infections used.

These are parasitic infections caused by the opportunistic Pathogens Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp. triggered become.

The pharmaceutical compositions of the invention or the Compounds of the general formula (I) can furthermore be used for Infection prophylaxis of blood and blood products are used.

Of particular importance are the compounds of general formula (I) and their pharmaceutical compositions according to the invention for controlling of gastrointestinal infection of HIV-immunosuppressed patients. Currently exists no effective drug for this indication. Further, the use is in veterinary point of view, since in the treatment of the Cocciodosis in poultry farming and trypanosomiasis in breeding cattle high demand for effective and non-toxic medicines.  

Synthesis of N ¹ -substituted naphthindazole-4,9-quinones

The synthesis of the compounds of general formula (I) is carried out according to the synthesis scheme described in German Patent DE 38 31 332. Accordingly, the naphthindazole-4,9-quinones of the general formula (I) are obtained by reacting the 5-arylmethylpyrazol-4-ylcarboxylic acid halides of the general formula (II)

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ^{6 have} the meanings given above and Hal is halogen, in an inert solubilizer in the presence of a Friedel-Crafts catalyst brings to reaction, and the compounds thus obtained the general formula (III),

wherein R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ^{6 have} the meanings given above, in the presence of a diluent with oxidizing agents in the naphthindazole-4,9-quinones of the general formula (I).

The following Examples 1 to 6 describe the study of leishmanicides and trypanocidal effect, the anti-malaria effect, the cryptosporidicidal action as well as the cytotoxic effect in vitro and in vivo.

Example 7 describes the provision of nanosuspensions for improvement the in vivo bioavailability of the compounds of general formula (I).

Example 8 deals with the improvement of in vivo bioavailability Incorporation of the compounds of general formula (I) in solid lipid Nanoparticles (SLN).

example 1 Studies of leishmanicidal activity EXTRACELLULAR CYTOTOXICITY AGAINST LEISHMANIA spec.

In her Vector (butterfly mosquito; Phlebotomidae) and in cell culture media Leishmania parasites live in their promastigote (elongated-flagellated) form. Living cells metabolize the yellow dye MTT [3- (4,5-dimethylthiazole-2-ol) yl) -2,5-diphenyltetrazolium bromide] to blue formazan crystals, which be quantified colorimetrically. Compared to untreated samples (Controls) indicate lower MTT sales to directly effective antiparasitic Effects.

This test allows a screening of substances. However, in the mammal Leishmania parasites after infection almost exclusively intracellular and in their Amastigote form, its meaning is less than an intracellular Cytotoxicity test (see there).

execution

• 1. promastigote Leishmania (L. donovani, L. major, L. enriettii) are à seeded 1 x 10 ^4/100 ul medium in 96-well microtiter plates.
• 2. Test and reference substances are added in dilution series.
• 3. The parasites are incubated at 25 ° C for 96 h.
• 4. During the last 6 h, MTT solution is added.  
• 5. Formazan is dissolved in sodium (SDS) dodecyl sulfate (SDS) and in the automatic ELISA device by absorbance measurement at 570 nm quantified.
• 6. Leishmanicidal effects are calculated as EC ₅₀ (drug concentration at 50% reduced MTT turnover compared to the untreated control).

INTRA-CELLULAR CYTOTOXICITY AGAINST LEISHMANIA spec.

Leishmania parasites are released from their obligatory host cells (macrophages, Monocytes) by phagocytosis. Some succeed in the establishment in the parasitophore vacuoles transformed into the physiologically adapted amastigote, which proliferates intracellularly and with the Disease is causally related. Anti-Leishmania remedies need also pass into the parasitophore vacuole and under the prevailing there Conditions as specific as possible against amastigote Leishmania parasites.

Macrophages already parasitized with Leishmania become active ingredients and Exposed to reference substances. After 96 hours, the host cells are dissolved. Surviving Leishmania transform into Promastigote and multiply. Living cells metabolize the yellow dye MTT [3- (4,5-dimethylthiazole-2-ol) yl) -2,5-diphenyltetrazolium bromide] to blue formazan crystals, which be quantified colorimetrically. Mean compared to untreated controls lower MTT turnover on intracellular antiparasitic effects.

execution

• 1. Murine bone marrow culture macrophages (MΦ) are using promastigoten Leishmania (L. donovani, L. major, L. enriettii).
• 2. After 1 h, extracellular Leishmania are removed by centrifugation, the seeded MΦ in microtiter plates and incubated at 37 ° C.
• 3. After 24 h, test and reference substances are in dilution series added.
• 4. After 96 hours, MΦ are selectively lysed by SDS.  
• 5. The lysate is incubated for 72 h in Leishmania growth medium at 25 ° C.
• 6. MTT solution is added for the last 6 hours.
• 7. Formazan formate is dissolved in SDS and in the automatic ELISA device quantified by absorbance measurement at 570 nm.
• 8. Leishmanicidal effects are calculated as EC ₅₀ (drug concentration at 50% reduced MTT turnover compared to the untreated control).

Results

Table 1

Leishmanicidal activity of exemplary naphthindazole-4,9-quinones against different Leishmania species, indicating EC ₅₀ in μg / ml

Example 2 Investigations of the trypanocidal effect

The determination of the trypanziden effectiveness takes place after WHO recommendations, which by Croft and Kaminsky (Croft, S.L., Kaminsky, R. (1997a), Standardization of Drug Screening, Communication to COST ACTION 815 Acrival, Louvain) were.

execution

In vitro determination of activity against Trypanosoma b. brucei

• 1. The effect is determined in the in vitro test model with 2 different Trypanosoma strains. The fabrics were as above indicated solved.
• 2. The test is based on that of Brun and Lun (Brun R, Lun (1994), Vet. Parasitol. 52, 37-46)) described LILI test (Low Inoculum Long Incubation Test).
• 3. Starting at 30 mg / ml, test substances are placed in a 96-well microtiter plate (250 μl) 1: 2 titrated linearly in medium.
• 4. T. brucei (4 × 10 ³ / ml) is added to 50 μl Balz medium / hole, the plates incubated at 37 ° C for 72 h.
• 5. MTT solution is added for the last 5 hours. Determination of relative Parasite growth occurs after visual control of MTT turnover by surviving trypanosomes.

In vitro determination of activity against Trypanosoma cruzi

The determination of the trypanziden effectiveness takes place after WHO recommendations, which by Croft and Kaminsky, 1997, (Croft, S.L., Kaminsky, R. (1997a), Standardization of Drug Screening, Communication to COST ACTION 815 Acrival, Louvain) were.

execution

• 1. As Host Cells, BALB7c Mice After Induction with 2% Starch solution, i. p. Obtained 24 hours before lavage, peritoneal macrophages.
• 2. The infection is caused by trypomastigote, gained from the overlay infected WI-38, Vero cells or L6 myoblasts. The infection ratio host: parasite is 1: 5.
• 3. The infected cells in a 24-well microtiter plate become one Drug concentration of 30 .mu.mol exposed in a threefold Dilution series are dilute.
• 4. Incubation takes 3-6 days.
• 5. The determination of trypanocidal effects is done visually with the help of a Inverted microscope.

Results

Table 2

Trypanocidal action of exemplary naphthindazole-4,9-quinones against Trypanosoma b. brucei, indication of EC ₅₀ in μg / ml

Example 3 Investigations on the anti-malaria effect

Freshly transferred Plasmodium spec. first go through a short intra hepatocytic stage and then ongoing intra-erythrocytic cycles. The erythrocytic cycle of human pathogenic P. falciparum is completely in vitro comprehend.

The stages of development within the erythrocytes can be based on dyed, microscopic preparations are tracked and quantified. The proportion of parasitized Erythrocytes compared to the untreated control indicates the inhibition of close intracellular multiplication, while the relative proportions of the individual Developmental stages first conclusions about the mode of action of a substance allow.  

execution

• 1. 7-day-old P. falciparum blood cultures are added to fresh donor blood and sown in microtiter plates.
• 2. Addition of different concentrations of test and reference substances.
• 3. Incubation 24 h and 48 h at 37 ° C.
• 4. At both times. Preparation of microscopic preparations / sample; coloring to Giemsa.
• 5. Counting of 4 visual fields / specimen.
• 6. Evaluation according to:
  • -% parasitized erythrocytes,
  • - Share ring stage, trophozoites, schizonts.

Results

Table 3

Antiplamosdial effect of exemplary naphthindazole-4,9-quinones against Plasmodium falciparum, indication of EC ₅₀ in μg / ml

Example 4 Investigation to inhibit cryptosporidiosis In vitro activity against Cryptosporidium parvum

Cryptosporidium parvum (C. parvum) strains KSU-1 and Iowa were prepared by Dr. med. M. V. Nesterenko (Kansas State University). Oocysts were with CsCl solution or by centrifugation in a sucrose gradient, for Sterilization for 5 min in Chlorox® solution and then with sterile  Washed water. For in vivo excystation, purified oocysts were at 37 ° C for 1 hour in PBS buffer with 0.25% trypsin and 0.75% taurodeoxycholate incubated. Free sporozoites were purified by centrifugation in the Percoll® gradient isolated. The procedure is based on the instructions of Nesterenko, MV, Upton, SJ (1996) J. Microbiol. Meth., 25: 87-89. The investigation of the anti-Cryptosporidien- Effect according to the regulations of Woods, KM, Nesterenko, MV (1995) FEMS Microbiol. Lett, 128: 89-94. The compounds of the general formula (I) which Naphthindazole-4,9-quinones were tested as follows:

execution

• 1. oocysts are given à 3.0 × 10 ^4/100 ul medium in 96-well microtiter plates in which 4.0 × 10 ⁸ HCT-8 cells (ATCC CCI 244) were sown.
• 2. Plates are incubated for 90 min at 37 ° C and washed twice.
• 3. New nutrient medium and test-like reference substances are in Dilution series added.
• 4. The parasites are incubated for 48 h at 37 ° C, 5% CO ₂ , 95% humidity.
• 5. Detection is carried out by ELISA measurement with rat anti-cryptosporidium Antiserum.
• 6. After addition of 3,3 ', 5,5'-tetramethylbenzidine, the optical density at 630 nm quantified in the automatic ELISA device.
• 7. Anti-Cryptosporidium effects are calculated as EC ₅₀ .

In vivo activity against Cryptosporidium parvum

C. parvum is a major and common cause of diarrhea among calves and the most severe diarrhea in immunocompromised people. CD4 ⁺ T Cell-defective (TCR-α-deficient) mice are unable spontaneously to eliminate the pathogen.

At least one of the compounds of the general formula (I) is administered orally. You must resist the conditions and the duration of gastric passage and  unfold their effectiveness on the intestinal epithelium. Counted are C. parvum sporozoites on a defined area of small intestinal epithelium. Indicated is the reduction of Colonization (in%) compared to untreated control animals.

execution

• 1. C. parvum-sensitive TCR-α-deficient mice are administered orally with C. parvum Oocysts infected.
• 2. Test and reference substances are administered orally.
• 3. animals are killed; The small intestinal epithelium is prepared.
• 4. C. parvum sporozoites are counted.

Results

Table 4

Effect of exemplary naphthindazole-4,9-quinones against Cryptosporidium parvum, indication of EC ₅₀ in μg / ml

Example 5 Studies on cytotoxic effects in vitro and in vivo In vitro studies

We are looking for active ingredients with the highest possible toxicity for individual groups or groups of pathogens and, at the same time, low toxicity to cells of the Host organism.

Living cells metabolize the yellow dye MTT [3- (4,5-dimethylthiazole-2-ol) yl) -2,5-diphenyltetrazolium bromide] to blue formazan crystals, which be quantified colorimetrically. Compared to untreated controls Lower MTT sales indicate cytotoxic effects.

The following were investigated:
Mouse: Bone marrow culture macrophages
Mouse: monocyte line RAW
Human: melanoma line SK-Mel
Human: Line Hela.

execution

• 1. Cells are seeded at 1 x 10 ^5/100 ul medium / well in 96-well microtiter plates and incubated for 1 h at 37 ° C.
• 2. Test and reference substances are serial dilutions in 100 μl / well added.
• 3. Incubation time 48 h or 72 h, of which the last 6 h in the presence of MTT Solution.
• 4. Formazan is dissolved by means of SDS and placed in an automatic Quantified ELISA device by determining the relative absorbance at 570 nm.
• 5. Cytotoxic effects are calculated as EC ₅₀ (drug concentration at 50% reduced MTT turnover compared to the untreated sample).

In vivo studies

Parallel to the studies on the efficacy of test substances in vivo against Cryptosporidium parvum (R. Waters) or L. donovani (S. Croft) were not treated infected animals by the same route (oral or intravenous) to a first Impression of possible side effects of the compounds of the general formula (I) to get the whole organism.

execution

• 1. Mice are given oral test or reference substances.
• 2. Animals are observed for:
  • - mortality
  • - attitude
  • - Behavior
  • - external appearance (condition of the coat, food intake).

Results

Table 5

In vitro cytotoxicity determination of naphthindazole-4,9-quinones, EC ₅₀ = μg / ml

Example 6 Studies on in vivo activity against Leishmania donovani

Leishmania donovani are obligate intracellular parasites of the monocyte Macrophage system. They cause visceralizing infections below Involvement of all organs, including bone marrow. Usually it is a zoonotic disease, including rodents as a reservoir serve. The infection of the mouse thus offers a widespread infection model similar symptoms as in humans (visceralization of the pathogen, Hepatosplenomegaly, u. a. m.) with genetically determined, d. H. Mausstamm- dependent tendency to self-healing or chronicity.

execution

• 1. Leishmania donovani strain MHOM / ET / 67 / L82 (HU3 or LV9) or Leishmania donovani strain LRC-1233 (WHO Reference Center Jerusalem) mouse strain BALB / c, female, 18-20 g,
• 2. Therapy Standards: Sodium Stibogluconate (Pentostamâ, Glexo-Wellcome), Meglumine antimonate (Glucantimeâ, Rhone-Poulenc Rover),
• 3. Test substances are usually in 100% DMSO or ethanol recorded (stocks of 10 mM prepared). Before each application fresh serial dilutions of these stocks (90 μM) in culture medium or PBS manufactured.
• 4. Mice are infected either with metacyclic promastigotes (from in vitro cultures) intraperitoneally (ip) or amastigotes (from infected hamsters) intravenously (iv) at 1 x 10 ⁷ parasites / mouse.
• 5. Treatment with test substances or therapy standards begins 7-10 d p. i. With One dose per day over the next 4-5 days.
• 6. At various times the animals are killed, spleen and liver Weighed and prepared from each organ swab specimens, which in methanol (100%) fixed and stained according to Giemsa (10%, 45 min).  
• 7. Count the number of amastigotes per liver cell and the total number of parasites / organ calculated according to the formula:
  Number of amastigotes / 500 cells × organ weight [mg] × 200,000 (constant).

Results

The corresponding test results are summarized in Table 1.

Example 7 Improvement of in vivo bioavailability by conversion into Nano suspensions

By nano-suspensions on the spontaneous readiness of the above Targeting cells to take in foreign bodies represent nanosuspensions as particulate dosage forms an effective "drug-targeting" against pathogens, which persist within phagocytes (macrophages). So can be selective high drug concentrations achieved by the pathogen and the burden of the rest Organism be minimized. Furthermore, they show the big advantage through Particle size reduction and surface enlargement the low solubility of Compounds of general formula (I), naphthindazole-4,9-quinones improve.

execution

The preparation of nanosuspensions of the compounds of the general formula (I) is carried out under pressure using a high-pressure homogenizer LAB 40 200 to a maximum of 1500 bar and use of different numbers of cycles (i. 4-8 cycles) [R. H. MÜLLER and K. PETERS, Int. J. Pharmaceutics 1998, 160, 229-237]. The average particle diameter is in the range of about 50 to 999 nm. Sterilization is by autoclaving. Alternatively, a aseptic production under laminar air flow (LAF). The particle size is using the photon correlation spectroscopy PCS (Malvern Zetasizer), a Laser diffractometer LD and a Coulter Counter with 30 μm capillary (Coulter Electronics). The particle size is indicated for the characterization of the  Nanosuspension by their diameters (D50%, D90% and D99%). to Determination of the saturation concentration in the supernatant, the separation takes place in a high-speed centrifuge and then measuring the connection of general formula (I), of naphthindazole-4,9-quinone, with the aid of UV Spectroscopy.

To set the highest possible physical storage stability (absence of particle aggregation), it is favorable, the particles as high as possible in the same direction charge (high zeta potential). Charging is optimized by selecting charged surfactants made, the charge achieved by electrophoresis measurements (use of laser Doppler anemometry - LDA). The low Solubility in biological media of the compounds of general formula (I), which Naphthindazole-4,9-quinone proves to be beneficial for systemic application as a nanosuspension. The compounds of general formula (I) are characterized by High pressure homogenization transferred into a nanosuspension and thus intravenously made applicable. By transferring sparingly water-soluble compounds of general formula (I) in nanosuspensions may have sufficient bioavailability availability and optimized delivery of the compound of general formula (I) into infected Macrophages can be achieved in the animal model. Testing for physical stability, Release of the compound of general formula (I) and review of Saturation solubility is achieved by repeated particle size determination and UV Spectroscopic examinations (HPLC if necessary) in a defined time interval.

Example 8 Improvement of in vivo bioavailability by formulation as solid lipid Nanoparticles (SLN)

The compound of the general formula (I) is dissolved in a fatty base or suspended, which after cooling with the help of high-pressure homogenization, as under Example 7, to particles with an average size of 100-900 nm is homogenized. An advantage over pure nanosuspensions  is that defined particles are generated, for example, higher cell affinity , reduce the toxicity of drugs, a drug release after allow defined kinetics and for gastrointestinal as well as cellular targeting are suitable.

execution

The naphthoquinone SLN is prepared by cold homogenization Technique: The fat basis (for example Compritol ATO 888, Poloxamer 188) becomes melted, the compound of general formula (I), the naphthindazole-4,9- quinone, added to the melt and stirred cold. The solidified melt, which the compound of general formula (I) dissolved or suspended, is with Addition of, for example, Tween 80 and Span crushed with an Ultra-Thurax. This solution or presuspension is subsequently used with a LAB-40 Homogenizer homogenized directly to particles in the range 100-900 nm receive. These particles are called Solid Lipid Nanoparticles (SLN). The Particle size is determined using photon correlation spectroscopy PCS (Malvern Zetasizer), a laser diffractometer LD and a Coulter Counter with 30 μm Capillary (Coulter Electronics) determined. The particle size is given for Characterization of the nanosuspension by their diameters (D50%, D90% and D99%). To determine the saturation concentration in the supernatant takes place Separation in a high speed centrifuge and the measurement of the Compound of general formula (I), naphthindazole-4,9-quinone, with the aid of UV spectroscopy.

Claims (12)

1. Pharmaceutical compositions, characterized by the content of at least one of the compounds of general formula (I)
wherein R ^{1 is} a hydrogen atom or a group
- (CH ₂ ) _m -CH = CH- (CH ₂ ) _8-m -H,
- (CH ₂ ) _m -C-C- (CH ₂ ) _8-m -H,
- (CH ₂ ) _n -R ⁷ ,
-C ₂ H ₄ -C~CR ¹² ,
-CH ₂ -C~C-CH ₂ -R ¹² ,
-C~CC ₂ H ₄ -R ¹²
means and
R ² , R ³ , R ⁴ , R ⁵ and R ⁶ are each independently a hydrogen atom or one of the radicals
R ⁷ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN, -OH,
- (CH ₂ ) _o -R ¹⁴ ,
-O- (CH ₂ ) _o -R ¹² ,
-S- (CH ₂ ) _o -R ¹² ,
represent
R ³ together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{3 forms} together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring another condensed five- or six-membered heterocycle, wherein R ³ and R ⁴ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁴ together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{4 forms} together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring another condensed five- or six-membered heterocycle, wherein R ⁴ and R ⁵ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁵ together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring forms a further fused benzene or naphthalene ring, which optionally carries further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{5 forms} together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring another fused five- or six-membered heterocycle, wherein R ⁵ and R ⁶ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ^{7 is} -R ¹² , -OR ⁸ or -SR ⁸ ,
R ⁸ and R ^{8 'are} independently of one another an alkyl group having 1 to 4 carbon atoms,
R ^{9 is} an alkyl group having 1 to 4 carbon atoms or a group of the structure
-NH-R ⁸ ,
represents,
R ^{10 is} -R ¹² , -R ⁸ or -OR ⁸ ,
R ^{11 is} -R ⁸ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -OH, -OR ⁸ ,
R ¹² , -R ^{12 '} , -R ^{12 "} , -R ^12"' , -R ^{12 ""} independently of one another are -H, -F, -Cl, -Br or -I,
R ^{13 is} -R ⁸ , -R ¹² or a group of the following structure
-C ₂ H ₄ -C~CR ¹² , -CH ₂ -C~C-CH ₂ -R ¹² , -C~CC ₂ H ₄ -R ¹² ,
R ^{14 is} -CH ₃ , -R ⁷ or -SH,
R ¹⁵ , -R ^{15 '} , -R ^{15 "} , -R ^15"' , -R ^{15 ""} independently of one another
-R ⁷ , -R ⁸ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN or
-O- (CH ₂ ) _o -R ¹² , -S- (CH ₂ ) _o -R ¹² , - (CH ₂ ) _o -R ¹²
stand,
R ¹⁶ and R ^{16 '} independently of one another denote -H or -R ⁸ ,
R ^{17 is} -R ⁷ , -CF ₃ , -NO ₂ , -CN, -SH, -OH or -NH ₂ ,
m for 0 to 8,
n for 1 to 10,
o for 1 to 5 and
p is 0 to 4,
and their pharmacologically acceptable salts and their dimers and trimers. 2. Pharmaceutical compositions according to claim 1, characterized in that it is applied alone or in a known manner Stretching the active substance with solvents, carriers and / or animal feed, optionally using emulsifiers and / or dispersants be translated into the usual formulations and as solutions, Suspensions, dispersions, emulsions, creams, ointments, pastes, powders, Granules, tablets, suppositories, capsules or dragees are used. 3. Pharmaceutical compositions according to at least one of the claims 1 or 2, characterized in that as the solvent aromatics, chlorinated Aromatics, paraffins, alcohols, water, ketones, amines, ethanolamine, Dimethylformamide, dimethylsulfoxide, as carriers natural minerals,  Kaolin, clays, talc, chalk or ground synthetic minerals, highly disperse silica or silicates, as emulsifiers nonionic and ionic emulsifiers, polyoxyethylene fatty alcohol ethers, alkyl sulfonates, Arylsulfonate, as a dispersant lignin, liquors, methyl cellulose and as Capsule bases for tablets ethylcellulose, starch, lactose, alkaline-earth Fatty acids or magnesium stearate can be used. 4. Pharmaceutical compositions according to at least one of the claims 1 to 3, characterized in that the antiparasitic pharmaceutical Compositions between 0.1 and 99 wt .-% of at least one of Compounds of general formula (I) included. 5. Pharmaceutical compositions according to claim 4, characterized characterized in that the antiparasitic pharmaceutical Compositions between 50 and 99 wt .-% of at least one of Compounds of general formula (I) included. 6. Pharmaceutical compositions according to at least one of the claims 1 to 5, characterized in that these pharmaceutical compositions the patient depending on the clinical picture and the physi stature of the patient with a daily dose of between 0.5 and 1500 mg be administered based on the compounds of general formula (I). 7. Pharmaceutical compositions according to at least one of the claims 1 to 6, characterized in that a processing of the compounds of general formula (I) for systemic and local administration to particulate Drug forms takes place. 8. Pharmaceutical compositions according to claim 7, characterized characterized in that the particulate pharmaceutical forms um Nanosuspensions, Solid Liquid Nanoparticles (SLN) or liposomes with a average particle diameter of 0.1 to 3 microns is.   9. Use of the compounds of general formula (I)
for the prophylactic administration or therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp.,
wherein R ^{1 is} a hydrogen atom or a group
- (CH ₂ ) _m -CH = CH- (CH ₂ ) _8-m -H,
- (CH ₂ ) _m -C-C- (CH ₂ ) _8-m -H,
- (CH ₂ ) _n -R ⁷ ,
-C ₂ H ₄ -C~CR ¹² ,
-CH ₂ -C~C-CH ₂ -R ¹² ,
-C~CC ₂ H ₄ -R ¹²
means and
R ² , R ³ , R ⁴ , R ⁵ and R ⁶ are each independently a hydrogen atom or one of the radicals
R ⁷ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN, -OH,
- (CH ₂ ) _o -R ¹⁴ ,
-O- (CH ₂ ) _o -R ¹² ,
-S- (CH ₂ ) _o -R ¹² ,
represent
R ³ together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ³ together with R ⁴ and the two carbon atoms C-5 and C-6 of the benzene ring forms a further fused five- or six-membered heterocycle, wherein R ³ and R ⁴ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁴ together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring forms a further condensed benzene or naphthalene ring, which optionally bears further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{4 forms} together with R ⁵ and the two carbon atoms C-6 and C-7 of the benzene ring another condensed five- or six-membered heterocycle, wherein R ⁴ and R ⁵ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ⁵ together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring forms a further fused benzene or naphthalene ring, which optionally carries further functional groups, wherein these functional groups are fluorine, chlorine, bromine , Iodo, nitro, cyano, amino, hydroxy, trifluoromethyl groups, alkyl groups of 1 to 5 carbon atoms, alkoxy or haloalkoxy groups of 1 to 5 carbon atoms or alkylthio or haloalkylthio groups of 1 to 5 carbon atoms,
R ^{5 forms} together with R ⁶ and the two carbon atoms C-7 and C-8 of the benzene ring another fused five- or six-membered heterocycle, wherein R ⁵ and R ⁶ are each independently a carbon, oxygen or nitrogen atom and this further Heterocycle is optionally substituted by fluorine, chlorine, bromine, iodine or alkyl radicals having 1 to 4 carbon atoms,
R ^{7 is} -R ¹² , -OR ⁸ or -SR ⁸ ,
R ⁸ and R ^{8 'are} independently of one another an alkyl group having 1 to 4 carbon atoms,
R ^{9 is} an alkyl group having 1 to 4 carbon atoms or a group of the structure
-NH-R ⁸ ,
represents,
R ^{10 is} -R ¹² , -R ⁸ or -OR ⁸ ,
R ^{11 is} -R ⁸ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -OH, -OR ⁸ ,
R ¹² , -R ^{12 '} , -R ^{12 "} , -R ^12"' , -R ^{12 ""} independently of one another are -H, -F, -Cl, -Br or -I,
R ^{13 is} -R ⁸ , -R ¹² or a group of the following structure:
-C ₂ H ₄ -C~CR ¹² , -CH ₂ -C~C-CH ₂ -R ¹² , -C~CC ₂ H ₄ -R ¹² ,
R ^{14 is} -CH ₃ , -R ⁷ or -SH,
R ¹⁵ , -R ^{15 '} , -R ^{15 "} , -R ^15"' , -R ^{15 ""} independently of one another
-R ⁷ , -R ⁸ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} , -CN or
-O- (CH ₂ ) _o -R ¹² , -S- (CH ₂ ) _o -R ¹² , - (CH ₂ ) _o -R ¹²
stand,
R ¹⁶ and R ^{16 '} independently of one another denote -H or -R ⁸ ,
R ^{17 is} -R ⁷ , -CF ₃ , -NO ₂ , -CN, -SH, -OH or -NH ₂ ,
m for 0 to 8,
n for 1 to 10,
o for 1 to 5 and
p is 0 to 4,
and their pharmacologically acceptable salts and their dimers and trimers. 10. Use of the compounds of general formula (I) for the prophylactic administration or therapeutic treatment of a parasitic infection according to claim 9, characterized in that
R ^{1 is} hydrogen or a group
- (CH ₂ ) _m -CH = CH- (CH ₂ ) _2-m -H,
- (CH ₂ ) _m -C-C- (CH ₂ ) _2-m -H,
- (CH ₂ ) _n -R ⁷ ,
stands,
R ^{7 is} -R ¹² , -OR ⁸ or -SR ⁸ ,
R ⁸ and R ^{8 '} independently of one another denote an alkyl group having 1 to 4 carbon atoms,
R ¹² , R ^{12 '} , R ^12'' , R ^12''' , R ^{12 ''''} independently of one another are -H, -F, -Cl, -Br or -I,
R ¹⁵ , -R ^{15 '} , -R ^{15 "} , -R ^15"' , -R ^{15 ""} independently of one another
R ⁷ , R ⁸ , -NO ₂ , -NH ₂ , -NHR ⁸ , -NR ⁸ R ^{8 '} or -CN are and
m for 0 to 2 and
n stands for 1 to 4. 11. Use of the compounds of general formula (I) for the prophylactic administration or therapeutic treatment of a parasitic infection according to claim 9, characterized in that
R ^{1 is} hydrogen, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, tert-amyl, n-hexyl, pent-3-yl, 1,2 -Dimethylpropyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, 1,2,2-trimethylpropyl, 2-methylhept-5-yl, allyl, methallyl, crotyl, 2-ethyl-2-hexenyl, 5-hexenyl , 2-methyl-2-butenyl, 2-methyl-3-butenyl, 1-buten-3-yl, 2-methyl-1-buten-4-yl, 2-methyl-2-buten-4-yl, 3 -Methyl-1-buten-3-yl, propargyl, 1-butyn-3-yl, 2-butynyl, 2-chloroethyl, 2-chloropropyl, 3-chloropropyl, 2-chlorobut-2-yl, 2-chloro-2 methylpropyl, 2-fluorobut-2-yl, 2-fluoro-2-methylpropyl, 1-fluoroprop-2-yl, 1-chloro-2-methylprop-2-yl, 2,2,2-trifluoroethyl, hydroxymethyl, 2 -Hydroxyethyl, 3-hydroxypropyl, 1-hydroxyprop-2-yl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-2-methylpropyl, 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl, 1-methoxyprop 2-yl, 3-methoxybutyl, 1-methoxybut-2-yl, 1-methoxy-2-methylprop-2-yl, 1-ethoxy-2-methylprop-2-yl, 2-methoxybutyl, 4-methoxybutyl, cyclo propyl, cyclopentyl, cyclohexyl, 2-methylmercaptoethyl, 2-ethylmercaptoethyl, 3-methylmercaptopropyl, 3-methylmercaptobutyl, 1-methylmercaptobut-2-yl, 1-methylmercapto-2-methylprop-2-yl, 2-methylmercaptobutyl, phenyl, 4- Chlorophenyl, 3,4-dichlorophenyl, o-tert-butylphenyl, m-tert-butylphenyl, p-tert-butylphenyl, o-methoxyphenyl, m-methoxyphenyl, p-methoxyphenyl, o-methylphenyl, m-methylphenyl, p Methylphenyl, 4-methoxy-3-chlorophenyl, 2-methyl-4-chlorophenyl, benzyl, 2,6-dichlorobenzyl, 2-chloro-6-fluorobenzyl, 2,6-difluorobenzyl, o-chlorobenzyl, m-chlorobenzyl or p -Chlorbenzyl stands. 12. Use of the compounds of general formula (I) according to one of Claims 9 to 11 for infection prophylaxis of blood and blood products.